Vanguard Group Inc Nrx Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Nrx Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,440,045 shares of NRXP stock, worth $3.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,440,045

Previous 1,445,177 0.36%

Holding current value

$3.74 Million

Previous $664,000 1.81%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.29 - $0.7 $1,488 - $3,592	-5,132 Reduced 0.36%	1,440,045 $676,000
Q4 2023 Feb 14, 2024	SELL	$0.26 - $0.47 $1,408 - $2,545	-5,416 Reduced 0.37%	1,445,177 $664,000
Q3 2023 Nov 14, 2023	SELL	$0.23 - $0.5 $6,338 - $13,780	-27,560 Reduced 1.86%	1,450,593 $377,000
Q1 2023 May 15, 2023	BUY	$0.66 - $1.4 $23,093 - $48,986	34,990 Added 2.42%	1,478,153 $975,000
Q4 2022 Feb 10, 2023	BUY	$0.79 - $1.48 $2,289 - $4,289	2,898 Added 0.2%	1,443,163 $1.6 Million

Q3 2022 Nov 14, 2022	BUY	$0.2 - $0.82 $69,110 - $283,352	345,552 Added 31.57%	1,440,265 $1.07 Million
Q2 2022 Aug 12, 2022	BUY	$0.51 - $2.42 $9,891 - $46,938	19,396 Added 1.8%	1,094,713 $657,000
Q1 2022 May 13, 2022	SELL	$2.45 - $5.04 $237,444 - $488,456	-96,916 Reduced 8.27%	1,075,317 $2.63 Million
Q4 2021 Feb 14, 2022	BUY	$4.5 - $11.91 $774,495 - $2.05 Million	172,110 Added 17.21%	1,172,233 $5.6 Million
Q3 2021 Nov 12, 2021	BUY	$8.52 - $24.77 $3.09 Million - $8.98 Million	362,707 Added 56.9%	1,000,123 $9.27 Million
Q2 2021 Aug 13, 2021	BUY	$11.62 - $44.5 $7.41 Million - $28.4 Million	637,416 New	637,416 $7.41 Million

Others Institutions Holding NRXP

# of Institutions

Shares Held

3.74M

Call Options Held

64.6K

Put Options Held

9.6K

View Full List

About NRX Pharmaceuticals, Inc.

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $176M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

More about NRXP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Nrx Pharmaceuticals, Inc. Transaction History